



Resource impact summary report

Resource impact

Published: 28 August 2025

www.nice.org.uk

Contents

Resource impact summary report 3

 Recommendation 3

 Eligible population for idebenone 3

 Treatment options for the eligible population 4

 Financial resource impact (cash items) 4

 Capacity impact 5

 Key information..... 5

 About this resource impact summary report..... 6

Resource impact summary report

This summary report is based on the NICE assumptions used in the [resource impact template](#). Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect local data and assumptions.

Recommendation

Idebenone is recommended, within its marketing authorisation, as an option to treat visual impairment in Leber's hereditary optic neuropathy (LHON) in people 12 years and over.

Idebenone is recommended only if the company provides it according to the commercial agreement.

Eligible population for idebenone

Table 1 shows the population eligible for idebenone and the number of people expected to have idebenone in each of the next 5 years, including forecast population growth.

Table 1 Population expected to be eligible for and to have idebenone in England

Eligible population and uptake	Number of people eligible for idebenone	Uptake for idebenone (%)	Number of people starting treatment each year (if applicable)	Number of people continuing treatment from previous years (if applicable)	Number of people having idebenone each year
Current practice without idebenone	250	0%	0	0	0
Year 1	250	75%	188	0	188
Year 2	51	90%	46	188	233
Year 3	51	90%	46	233	279
Year 4	101	90%	47	92	139

Eligible population and uptake	Number of people eligible for idebenone	Uptake for idebenone (%)	Number of people starting treatment each year (if applicable)	Number of people continuing treatment from previous years (if applicable)	Number of people having idebenone each year
Year 5	72	90%	47	93	140

The following assumptions have been used to calculate the eligible population:

- There are about 1,500 people in England with LHON.
- Expert clinical opinion is that about 250 people will be eligible for treatment with idebenone (the prevalent population).
- About 50 people are expected to be diagnosed with LHON each year (the incident population) who are also eligible for treatment with idebenone.
- In year 1, 75% of the prevalent population are treated. By year 2, the prevalent population has decreased by 50 people, so it is assumed that all the prevalent population has been treated.

The uptake for idebenone is based on a combination of estimates from the company and NHS England's submissions.

Treatment options for the eligible population

The comparator treatment for the eligible population is best supportive care. Idebenone, which is an oral treatment, will be used in addition to standard care.

For more information about the treatments, such as dose and average treatment duration, see the [resource impact template](#).

Financial resource impact (cash items)

The company has a [commercial arrangement](#). This makes idebenone available to the NHS with a discount.

Users can input the confidential price of idebenone and amend other variables in the [resource impact template](#).

The payment mechanism for the idebenone is determined by the responsible

commissioner and depends on the idebenone being classified as high cost.

For further analysis or to calculate the financial impact of cash items, see the [resource impact template](#).

Capacity impact

Table 2 shows the impact on capacity activity in each of the next 5 years.

Table 2 Capacity impact (activity) in England

Capacity impact	Number of additional ophthalmology follow-up appointments
Current practice (without idebenone)	0
Year 1	0
Year 2	375
Year 3	467
Year 4	184
Year 5	186

For further analysis or to calculate the financial capacity impact from a commissioner (national) and provider (local) perspective, see the [resource impact template](#).

Key information

Table 3 Key information

Time from publication to routine commissioning funding	90 days
Programme budgeting category	PBC 08X
Commissioner	NHS England
Providers	NHS Hospital trusts
Pathway position	First line

About this resource impact summary report

This resource impact summary report accompanies the [NICE idebenone appraisal guidance on idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over](#) and should be read with it.

ISBN: 978-1-4731-7178-7